Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial

Mark Y Chan, Karen W L Koh, Sock-Cheng Poh, Stephanie Marchesseau, Devinder Singh, Yiying Han, Faclin Ng, Eleanor Lim, Joseph F Prabath, Chi-Hang Lee, Hui-Wen Sim, Ruth Chen, Leonardo Carvalho, Sock-Hwee Tan, Joshua P Y Loh, Jack W C Tan, Karishma Kuwelker, R M Amanullah, Chee-Tang Chin, James W L Yip, Choy-Yee Lee, Juvena Gan, Chew-Yong Lo, Hee-Hwa Ho, Derek J Hausenloy, Bee-Choo Tai, A Mark Richards, IMMACULATE Investigators, Mark Y Chan, Karen W L Koh, Sock-Cheng Poh, Stephanie Marchesseau, Devinder Singh, Yiying Han, Faclin Ng, Eleanor Lim, Joseph F Prabath, Chi-Hang Lee, Hui-Wen Sim, Ruth Chen, Leonardo Carvalho, Sock-Hwee Tan, Joshua P Y Loh, Jack W C Tan, Karishma Kuwelker, R M Amanullah, Chee-Tang Chin, James W L Yip, Choy-Yee Lee, Juvena Gan, Chew-Yong Lo, Hee-Hwa Ho, Derek J Hausenloy, Bee-Choo Tai, A Mark Richards, IMMACULATE Investigators

Abstract

Importance: There are few data on remote postdischarge treatment of patients with acute myocardial infarction.

Objective: To compare the safety and efficacy of allied health care practitioner-led remote intensive management (RIM) with cardiologist-led standard care (SC).

Design, setting, and participants: This intention-to-treat feasibility trial randomized patients with acute myocardial infarction undergoing early revascularization and with N-terminal-pro-B-type natriuretic peptide concentration more than 300 pg/mL to RIM or SC across 3 hospitals in Singapore from July 8, 2015, to March 29, 2019. RIM participants underwent 6 months of remote consultations that included β-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB) dose adjustment by a centralized nurse practitioner team while SC participants were treated face-to-face by their cardiologists.

Main outcomes and measures: The primary safety end point was a composite of hypotension, bradycardia, hyperkalemia, or acute kidney injury requiring hospitalization. To assess the efficacy of RIM in dose adjustment of β-blockers and ACE-I/ARBs compared with SC, dose intensity scores were derived by converting comparable doses of different β-blockers and ACE-I/ARBs to a scale from 0 to 5. The primary efficacy end point was the 6-month indexed left ventricular end-systolic volume (LVESV) adjusted for baseline LVESV.

Results: Of 301 participants, 149 (49.5%) were randomized to RIM and 152 (50.5%) to SC. RIM and SC participants had similar mean (SD) age (55.3 [8.5] vs 54.7 [9.1] years), median (interquartile range) N-terminal-pro-B-type natriuretic peptide concentration (807 [524-1360] vs 819 [485-1320] pg/mL), mean (SD) baseline left ventricular ejection fraction (57.4% [11.1%] vs 58.1% [10.3%]), and mean (SD) indexed LVESV (32.4 [14.1] vs 30.6 [11.7] mL/m2); 15 patients [5.9%] had a left ventricular ejection fraction <40%. The primary safety end point occurred in 0 RIM vs 2 SC participants (1.4%) (P = .50). The mean β-blocker and ACE-I/ARB dose intensity score at 6 months was 3.03 vs 2.91 (adjusted mean difference, 0.12 [95% CI, -0.02 to 0.26; P = .10]) and 2.96 vs 2.77 (adjusted mean difference, 0.19 [95% CI, -0.02 to 0.40; P = .07]), respectively. The 6-month indexed LVESV was 28.9 vs 29.7 mL/m2 (adjusted mean difference, -0.80 mL/m2 [95% CI, -3.20 to 1.60; P = .51]).

Conclusions and relevance: Among low-risk patients with revascularization after myocardial infarction, RIM by allied health care professionals was feasible and safe. There were no differences in achieved medication doses or indices of left ventricular remodeling. Further studies of RIM in higher-risk cohorts are warranted.

Trial registration: ClinicalTrials.gov Identifier: NCT02468349.

Conflict of interest statement

Conflict of Interest Disclosures: Drs Chan, Chin, J. Tan, Ho, and Loh receive consultation honoraria from AstraZeneca. Drs Chan, Richards and Hausenloy receive research grant funding from AstraZeneca. Dr J. Tan reports grants from Medtronic and honorarium from Bayer, Roche Diagnostics, and Philips outside the submitted work. No other disclosures were reported.

Figures

Figure.. Enrollment, Randomization, and Follow-up
Figure.. Enrollment, Randomization, and Follow-up
NT-pro BNP indicates N-terminal pro–b-type natriuretic peptide. aRerandomized numbers and total randomized numbers are mutually exclusive. Ten participants had to be rerandomized because of carbon11–labeled acetate quality control failure in a position emission tomography substudy. bA total of 136 participants successfully underwent remote intensive management after baseline cardiac magnetic resonance imaging. cA total of 13 participants did not receive remote intensive management because 7 participants withdrew before baseline cardiac magnetic resonance imaging and 6 had claustrophobia. dA total of 139 participants underwent standard care after baseline cardiac magnetic resonance imaging. eA total of 13 participants did not receive standard care because 8 participants withdrew before baseline cardiac magnetic resonance imaging and 5 had claustrophobia. fPrimary analysis included participants who completed both baseline and follow-up cardiac magnetic resonance imaging scans and had images that were interpretable.

References

    1. Roth GA, Johnson C, Abajobir A, et al. . Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25. doi:10.1016/j.jacc.2017.04.052
    1. Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail. 2018;6(3):179-186. doi:10.1016/j.jchf.2017.09.015
    1. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-788. doi:10.1016/S0140-6736(03)14286-9
    1. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, et al. . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301
    1. Dargie HG. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-1390. doi:10.1016/s0140-6736(00)04560-8
    1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342(8875):821-828.
    1. Køber L, Torp-Pedersen C, Carlsen JE, et al. ; Trandolapril Cardiac Evaluation (TRACE) Study Group . A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333(25):1670-1676. doi:10.1056/NEJM199512213332503
    1. Arnold SV, Spertus JA, Masoudi FA, et al. . Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791-1801. doi:10.1016/j.jacc.2013.04.102
    1. Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016;1(2):147-155. doi:10.1001/jamacardio.2016.0001
    1. Rodriguez JA, Clark CR, Bates DW. Digital health equity as a necessity in the 21st Century Cures Act Era. JAMA. 2020;323(23):2381-2382. doi:10.1001/jama.2020.7858
    1. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992;11(13):1685-1704. doi:10.1002/sim.4780111304
    1. Birati E, Roth A. Telecardiology. Isr Med Assoc J. 2011;13(8):498-503.

Source: PubMed

3
Iratkozz fel